News | March 07, 2023
Sun Pharma completes acquisition of Concert Pharmaceuticals
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Clinical studies are expected to start in Q2 2023.
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
LG Chem will receive totaling up to $95.5 million for the China rights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
